Disorders of Sexual Development (DSD)

Overview & Terminology

• Definition: Discrepancy among chromosomal, gonadal, and genital sex.
• Nomenclature: Replaces historical, stigmatizing terms “intersex,” “pseudohermaphrodite,” and “hermaphrodite”.
• Incidence: Approximately 1 in 4,000 live births. Rises significantly if all hypospadias and cryptorchidism cases included.
• Pathogenesis: Disruption in complex endocrine, paracrine, and autocrine signaling networks directing fetal gonadal development.

Normal timeline of fetal sexual differntiation

Bipotential Phase (Weeks 4-6)

Gestational Age	Developmental Event	Genetic/Endocrine Correlate
4–6 Weeks	Urogenital ridge develops from intermediate mesoderm.	Requires WT1, SF1, GATA4 expression.
4–6 Weeks	Primordial germ cells migrate from hindgut to gonadal ridge.	Migration error causes germ cell deficiency or ectopic tumors.
33 Days	Fetal adrenal cortex visually distinct from developing gonad.	-

Male Differentiation: Testis & Genitalia

Gestational Age	Developmental Event	Genetic/Endocrine Correlate
6–7 Weeks	Primitive Sertoli cells appear; first evidence of testicular differentiation.	Triggered by SRY gene expression in supporting cells.
7–8 Weeks	Pre-Sertoli cells form testicular cords. Fetal Leydig cells appear.	Requires SOX9 expression; DMRT1 prevents transdifferentiation.
7–9 Weeks	Sertoli cells secrete Anti-Müllerian Hormone (AMH).	Promotes Müllerian duct regression.
8–12 Weeks	Leydig cells secrete testosterone (stimulated by placental hCG).	Testosterone stabilizes Wolffian ducts.
8–14 Weeks	Masculinization Programming Window (MPW).	Dictates ultimate phallic size potential.
9 Weeks	Cylindrical 2-mm phallus develops with genital swellings.	Conversion of testosterone to DHT required.
11 Weeks	Testicular compartments (tubular, interstitial) fully visualized.	-
12–14 Weeks	Urethral plate canalizes and fuses to form penile urethra.	Disruption causes hypospadias.
12–15 Weeks	Transabdominal phase of testicular descent begins.	Mediated by Leydig cell INSL3 and LGR8/RXFP2 receptor.
14 Weeks	External genitalia clearly masculine.	-
22–35 Weeks	Inguinoscrotal phase of testicular descent.	Androgen-dependent phase.

Female Differentiation: Ovary & Genitalia

Gestational Age	Developmental Event	Genetic/Endocrine Correlate
6–9 Weeks	Upregulation of female-specific genes (WNT4, CTNNB1).	FOXL2 represses SOX9 to suppress testicular pathway.
8 Weeks	Müllerian ducts fuse.	Midline epithelial septum degenerates forming uterus.
10–11 Weeks	Gonad histologically identified as ovary.	Epigenetic demethylation of inactive X chromosome completes.
11 Weeks	Clitoris prominent; urogenital sulcus lateral boundaries separate.	Vaginal plate appears via occlusion of uterovaginal canal.
12–16 Weeks	Oogonia enter meiotic prophase I becoming primary oocytes.	Requires granulosa cells to form primordial follicle; prevents atresia.
16–20 Weeks	Oogonial clusters breakdown; primordial follicles form.	Follicles arrest in diplotene stage until puberty.
20 Weeks	Minimal clitoral growth; well-defined labia majora; distinct urethral/vaginal openings.	Peak germ cell count reached (6.8 million).

Embryology & Normal Sexual Differentiation

Bipotential Gonad Phase

• Occurs between 4-6 weeks gestation.
• Germ cells migrate from hindgut celomic epithelium to gonadal ridge.
• Requires specific transcription factors for somatic cell development: WT1, SF1 (NR5A1), GATA4, CBX2, EMX2, LIM1.
• Pluripotent state maintains genes poised for activation/repression of male/female pathways.

Testicular Differentiation (46,XY)

• Initiated at 6-7 weeks by SRY gene on Y chromosome.
• SRY triggers SOX9 expression, crucial for Sertoli cell differentiation.
• Testis secretes two key hormones:
  • Anti-Müllerian Hormone (AMH): Secreted by Sertoli cells. Induces Müllerian duct regression.
  • Testosterone: Secreted by Leydig cells (stimulated by placental hCG). Stabilizes Wolffian ducts (vas deferens, epididymis, seminal vesicles).
• Dihydrotestosterone (DHT): Converted from testosterone via 5α-reductase type 2 in target tissues. Drives external male virilization (phallic growth, labioscrotal fusion, testicular descent).
• Insulin-like factor 3 (INSL3): Secreted by Leydig cells. Required for transabdominal testicular descent.

Ovarian Differentiation (46,XX)

• Independent of SRY.
• Driven by ovary-specific genes: WNT4, RSPO1, FOXL2, DAX1 (NR0B1).
• WNT4 and DAX1 suppress androgen synthesis and repress the testicular pathway.
• Absence of AMH permits Müllerian duct differentiation into fallopian tubes, uterus, upper vagina.
• Absence of androgens leads to Wolffian duct regression and female external genitalia differentiation (lower vagina, labia, clitoris).

Classification of Disorders of Sex Development

Category	Karyotype	Subtypes	Key Pathologies
Sex Chromosome DSD	45,X/46,XY46,XX/46,XY	Mixed Gonadal Dysgenesis Ovotesticular DSD	Mosaic loss of Y chromosome. Chimerism. Gonadoblastoma risk high.
46,XY DSD	46,XY	Gonadal Development: Complete/Partial Dysgenesis Androgen Synthesis: Enzyme deficiencies Androgen Action: AIS	WT1, SF1, SOX9, SRY defects. StAR, 3β-HSD, 17α-OH/17,20-lyase, 5α-reductase, 17β-HSD3.Androgen Receptor (AR) mutations.
46,XX DSD	46,XX	Androgen Excess: Fetal, Fetoplacental, Maternal Gonadal Development: Testicular or Ovotesticular	Congenital Adrenal Hyperplasia (21-OHD, 11β-OHD). Placental aromatase deficiency. Maternal virilizing tumors. SRY translocation.

Molecular Genetics & Specific Etiologies

46,XX DSD (Virilized Female)

Characterized by female internal genitalia (uterus, ovaries present) and virilized external genitalia.

Fetal Androgen Excess (Congenital Adrenal Hyperplasia)

• 21-Hydroxylase Deficiency (CYP21A2):
  • Most common cause of 46,XX DSD.
  • Autosomal recessive.
  • Decreased cortisol/aldosterone → Increased ACTH → Adrenal hyperplasia → Massive androgen overproduction.
  • Phenotype ranges from mild clitoromegaly to complete penile urethra.
  • Diagnosis: Markedly elevated 17-OH Progesterone (17-OHP).
• 11β-Hydroxylase Deficiency (CYP11B1):
  • Autosomal recessive. ~5% of CAH cases.
  • Virilization plus hypertension/hypokalemia (due to elevated 11-deoxycorticosterone).
  • Diagnosis: Elevated 11-deoxycortisol and 11-deoxycorticosterone.
• 3β-Hydroxysteroid Dehydrogenase Deficiency (HSD3B2):
  • Impairs conversion of Δ5 to Δ4 steroids.
  • Mild virilization in females (elevated DHEA).
  • Salt-wasting crisis.
• P450 Oxidoreductase (POR) Deficiency:
  • Essential electron donor for CYP21, CYP17, aromatase.
  • Virilization of XX fetus via alternative “backdoor” DHT synthesis pathway.
  • Associated with Antley-Bixler syndrome (craniosynostosis, radiohumeral synostosis).

Fetoplacental & Maternal Androgen Excess

• Placental Aromatase Deficiency (CYP19A1):
  • Impaired conversion of fetal androgens to estrogens.
  • Marked maternal virilization during pregnancy.
  • Female fetus born with labioscrotal fusion and clitoromegaly.
• Maternal Tumors: Luteoma of pregnancy, arrhenoblastoma, Krukenberg tumors.
• Iatrogenic: Maternal ingestion of progestational/androgenic drugs.

Disorders of Gonadal Development

• 46,XX Testicular DSD (XX Male):
  • SRY gene translocated to X chromosome during paternal meiosis (90% of cases).
  • Normal male external genitalia; small azoospermic testes.
  • SRY-negative cases (10%) linked to SOX9 duplication or RSPO1 mutation.
• Ovotesticular DSD (True Hermaphrodite):
  • Presence of both ovarian and testicular tissue (often ovotestis).
  • Most common karyotype is 46,XX.
  • External genitalia variable; asymmetrical development common.

46,XY DSD (Undervirilized Male)

Characterized by male karyotype with ambiguous or complete female external genitalia.

Disorders of Testicular Differentiation (Gonadal Dysgenesis)

• Complete failure leads to female phenotype (Swyer syndrome). Partial failure leads to genital ambiguity.
• High risk of gonadoblastoma in dysgenetic intra-abdominal testes.
• WT1 Mutations: Denys-Drash syndrome (nephropathy, Wilms tumor, ambiguous genitalia). Frasier syndrome (focal segmental glomerulosclerosis, XY sex reversal, gonadoblastoma).
• SOX9 Mutations: Campomelic dysplasia (short-limbed dwarfism, bowed femora, cleft palate). 75% show complete male-to-female sex reversal.
• SF1 (NR5A1) Mutations: Adrenal insufficiency combined with 46,XY gonadal dysgenesis and Mullerian persistence.
• DHH (Desert Hedgehog): Gonadal dysgenesis with minifascicular polyneuropathy.
• SRY Mutations: Responsible for 15-20% of XY gonadal dysgenesis cases. Prevents DNA-binding/bending.
• Testicular Regression Syndrome (Vanishing Testes): Normal external genitalia, absent testes. In utero ischemic insult post-differentiation.

Disorders of Androgen Synthesis

• Congenital Lipoid Adrenal Hyperplasia (StAR deficiency): Defective cholesterol conversion. Complete female phenotype in XY. Salt-wasting.
• 17α-Hydroxylase/17,20-Lyase Deficiency (CYP17A1): Blocks synthesis of DHEA/androstenedione. Female/ambiguous genitalia. Hypertension and hypokalemia.
• 17β-Hydroxysteroid Dehydrogenase Type 3 Deficiency (HSD17B3): Impairs conversion of androstenedione to testosterone. Female external genitalia with blind vaginal pouch, but Wolffian structures present. Massive virilization at puberty due to extratesticular conversion.
• 5α-Reductase Type 2 Deficiency (SRD5A2): Impaired conversion of T to DHT. Ambiguous genitalia (pseudovaginal perineoscrotal hypospadias). Severe pubertal virilization often leading to male gender role adoption. High T/DHT ratio (>17) post-hCG.

Disorders of Androgen Action

• Androgen Insensitivity Syndrome (AIS): X-linked recessive AR mutations.
  • Complete AIS (CAIS): Female external genitalia, blind vaginal pouch, absent uterus (AMH still active). Normal breast development at puberty (testosterone aromatized to estrogen). Primary amenorrhea presentation.
  • Partial AIS (PAIS): Wide spectrum (Reifenstein syndrome). Perineoscrotal hypospadias, bifid scrotum, gynecomastia at puberty.

Disorders of AMH Action

• Persistent Müllerian Duct Syndrome (PMDS): Mutations in AMH or AMHR2. Fully virilized male with bilateral cryptorchidism and retained uterus/fallopian tubes.

Sex Chromosome DSD

• Mixed Gonadal Dysgenesis (45,X/46,XY):
  • Extreme phenotypic variability.
  • Usually unilateral testis and contralateral streak gonad.
  • Müllerian structures present.
  • High risk of germ cell neoplasia (gonadoblastoma).

Syndromic Associations of DSD

Syndrome	Gene	Clinical Features
Smith-Lemli-Opitz	DHCR7	Microcephaly, 2-3 toe syndactyly, cleft palate, elevated 7-dehydrocholesterol.
CHARGE	CHD7	Coloboma, Heart defects, Choanal atresia, Retardation, Genital/Ear anomalies.
Pallister-Hall	GLI3	Hypothalamic hamartoma, postaxial polydactyly, imperforate anus, bifid epiglottis.
WAGR	11p13 del	Wilms tumor, Aniridia, Genitourinary anomalies, Retardation.
Hand-Foot-Genital	HOXA13	Short thumbs/great toes, hypospadias, bicornuate uterus.
Genitopatellar	KAT6B	Absent patellae, flexion contractures, ambiguous genitalia, agenesis corpus callosum.

Diagnostic Evaluation of DSD

Clinical History

• Family history of consanguinity, neonatal deaths (suggests CAH).
• Family history of infertility, amenorrhea, or delayed puberty (suggests X-linked AIS or enzymatic defect).
• Maternal virilization during pregnancy (aromatase deficiency, luteoma).
• Maternal drug ingestion (progestins, androgens).

Physical Examination

• General Exam: Dysmorphic features (syndromic DSD), hyperpigmentation (CAH/ACTH excess).
• Gonadal Palpation: Critical step. Bilateral palpable gonads below the inguinal ring are almost always testes (virtually excludes 46,XX CAH). Unilateral gonad suggests mixed gonadal dysgenesis or ovotesticular DSD.
• Phallic Assessment: Measure stretched penile length. Normal full-term male is >2.5 cm. Micropenis <2.5 cm. Assess chordee and hypospadias location.
• Labioscrotal Fusion: Prader staging (I to V).
• Anogenital Distance (AGD): Biomarker of prenatal androgen exposure.

Laboratory Investigations

• Tier 1 (Immediate):
  • Rapid karyotype and FISH (X and Y specific probes).
  • Serum electrolytes, glucose, blood gas (evaluate for salt-wasting/adrenal crisis).
  • Serum 17-OHP (drawn after 48 hours of life to minimize false positives, rules out 21-OHD).
• Tier 2 (Hormonal Profiling):
  • LH, FSH, Testosterone, DHT, Androstenedione, DHEA, AMH.
  • AMH serves as biomarker of Sertoli cell presence/function.
  • hCG Stimulation Test: Assesses Leydig cell capacity to synthesize testosterone and differentiates enzymatic blocks (e.g., T/DHT ratio for 5α-reductase deficiency, Androstenedione/T ratio for 17β-HSD3).
• Genetic Diagnostics:
  • Microarray (CGH), specific DSD gene panels, or whole exome sequencing (WES) to identify WT1, SF1, SOX9, SRY mutations.

Imaging and Surgical Evaluation

• Pelvic/Abdominal Ultrasound: Identifies presence/absence of uterus, fallopian tubes, and locating intra-abdominal gonads.
• Genitogram / Voiding Cystourethrogram: Determines level of vaginal fusion with urogenital sinus (critical for surgical planning).
• Laparoscopy & Gonadal Biopsy: Indicated for complex anatomical clarification and defining ovotesticular DSD versus dysgenetic testes.

Multidisciplinary Management & Therapeutic Strategies

The DSD Team & Psychosocial Support

• Composition: Pediatric endocrinologist, urologist/surgeon, geneticist, neonatologist, psychologist.
• Communication: Avoid gender-specific pronouns initially (use “your baby”). Utilize neutral terms (“gonads” instead of testes/ovaries).
• Reassure parents that condition is manageable and not their fault. Provide extensive psychological support to mitigate parental PTSD and anxiety.

Sex of Rearing Assignment

• Dictated by fertility potential, surgical feasibility, anatomical status, and natural history of the specific diagnosis.
• 46,XX CAH: Highly fertile. Almost universally reared female, regardless of degree of virilization.
• CAIS: Assigned and reared female due to complete phenotypic feminization.
• PAIS: Challenging. Depends on clinical response to exogenous testosterone. High dissatisfaction rate (25%) regardless of assignment.
• 5α-Reductase & 17β-HSD3 Deficiencies: Profound pubertal virilization. Reared male if diagnosed early, as many assigned female will spontaneously transition to male identity at puberty.

Medical Management

• CAH: Immediate physiological glucocorticoid (hydrocortisone) to suppress ACTH/androgens, plus mineralocorticoid (fludrocortisone) and salt supplementation for salt-wasters.
• Hypogonadism: Sex steroid replacement (estrogen or testosterone) instituted at expected age of puberty in incremental doses.
• Micropenis: Short course of low-dose intramuscular testosterone (e.g., 25 mg monthly x 3) in infancy to stimulate penile growth prior to surgery.

Surgical Interventions & Malignancy Risk

• Genitoplasty: Timing is highly controversial. Trend towards shared decision-making and delaying elective, irreversible surgeries until the patient can provide informed consent.
• Females (CAH): Vaginoplasty/clitoroplasty historically done early, but increasingly deferred to minimize compromised genital sensitivity and stenosis. Early surgery reserved for severe urogenital sinus risking urinary retention.
• Males (Hypospadias/Chordee): Multi-stage repair.
• Gonadectomy: Mandatory if Y-chromosome material (TSPY gene) is present in a dysgenetic streak gonad or intra-abdominal testis (e.g., Mixed Gonadal Dysgenesis, Swyer syndrome) due to 15-40% risk of gonadoblastoma/dysgerminoma.
  • In CAIS, gonadectomy is frequently deferred until post-puberty to allow spontaneous estrogen-induced breast development (aromatized from testicular testosterone).

Long-Term Outcomes & Prognosis

• Fertility: Excellent in optimally treated CAH. Usually absent in mixed gonadal dysgenesis, complete androgen insensitivity, and XX males. Assisted reproductive techniques (ART) such as microTESE increasingly successful.
• Bone Health: Patients with gonadal failure (e.g., Turner syndrome, CAIS post-gonadectomy) require optimal HRT to prevent severe osteopenia.
• Transition of Care: Structured handover to adult endocrinology and urology is imperative for ongoing hormone management, sexual function surveillance, and psychosocial support.